Challenging AI
In drug discovery, an AI-generated target ranking can influence experiments, portfolio choices and capital allocation long before a candidate enters clinical development. The...
Artificial intelligence is rapidly lowering the cost of generating plausible hypotheses in drug discovery. Models can nominate targets, integrate biological and chemical data, design...
RNA-based medicines have developed into a broad therapeutic platform. Clinically established modalities include antisense oligonucleotides, small interfering RNAs, messenger RNAs that direct transient protein...
Biomarker discovery lies at the heart of the translational gap in drug development. Too often, programs stall, and compounds fail in late-stage trials. Retrospective...
Developing a new medicine is difficult. Scientists must understand a disease, identify a biological target, find a compound or biologic that modulates it, and...
